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Abstract The RAS/RAF/MEK/ERK kinase pathway is
pivotal in the transduction of mitogenic stimuli from
activated growth factor receptors, which regulates cell
proliferation, survival, and diﬀerentiation. Up-regula-
tion of this pathway due to RAS mutations is found in
approximately 30% of human tumors. Recently, acti-
vating mutations of B-RAF were identiﬁed in a large
proportion of human cancers. Gliomas are the most
frequent primary central nervous system tumors and the
molecular mechanisms that underlie the development
and progression of these tumors are far from being
completely understood. The purpose of this study was to
clarify the incidence of B-RAF mutations and their
possible relation with tumor progression in a series of 82
human gliomas, including 49 astrocytic and 33 oligo-
dendroglial tumors. The analysis of B-RAF hotspot re-
gions, exons 11 and 15, showed presence of B-RAF
mutations in only 2 out of 34 (6%) glioblastomas, and
absence in the remaining histological types. Both
mutations were located in the hotspot residue 600
(V600E) at exon 15, which leads to constitutive B-RAF
kinase activity. These data suggest that activating
mutations of B-RAF are not a frequent event in gliomas;
nevertheless, when present they are associated with high-
grade malignant lesions.
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Introduction
Gliomas are the most frequent primary brain tumors in
children and adults [8]. Derived from neuroepithelial
cells, gliomas are a heterogeneous group composed of
diﬀerent histological and biological subtypes, including
astrocytic, oligodendroglial and mixed oligoastrocytic
tumors. These neoplasms are classiﬁed in four grades of
malignancy according to the World Health Organization
(WHO) classiﬁcation of brain tumors [10]. Glioblastoma
(WHO grade IV) is the most malignant and most com-
mon adult brain tumor. Despite multimodal treatment,
high-grade gliomas (e.g., glioblastoma) are highly inva-
sive and remain a challenge for oncology. The mean
survival time of glioblastoma patients is less than 1 year
and has changed little over the past three decades [6, 10,
20]. Thus, it is essential to clarify the yet poorly under-
stood molecular mechanisms that underlie the genesis
and progression of these tumors for the development of
novel therapeutic strategies.
The RAS/RAF/MEK/ERK intracellular signaling
cascade can be activated in response to a variety of
extracellular stimuli. Growth factor binding to extra-
cellular receptors results in activation of RAS, which in
turns induce the stimulation of downstream cellular
cascades (RAF/MEK/ERK, PI3K/AKT and RAC/
RHO pathways) that control cell proliferation, diﬀer-
entiation and survival [11]. The RAS/RAF/MEK/ERK
signaling cascade is frequently activated in human can-
cers, resulting in uncontrolled tumor growth [5].
Activating RAS mutations are found in approxi-
mately 30% of human cancers [5]; however, mutations
of RAS have been rarely identiﬁed in gliomas [2, 3].
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Nevertheless, several lines of evidence suggest that
alterations of RAS/RAF/MEK/ERK signaling are in-
volved in the development of gliomas. Using genetically
modiﬁed normal human astrocytes, Sonoda et al. [19]
recently deﬁne pathways critical to the development of
anaplastic astrocytoma, including RAS/RAF/MEK/
ERK pathway activation through mutant H-Ras. In
transgenic mouse models studies, overexpression of
oncogenic Ras in astrocytes and neural progenitors cells
lead to activation of RAS/RAF/MEK/ERK pathway
and induction of high-grade astrocytic tumors [4, 9].
Furthermore, Guha et al. [7] showed that the RAS
pathway is activated in glioblastomas. It is therefore
likely that mechanism other than RAS mutations acti-
vate the RAS/RAF/MEK/ERK pathway in gliomas.
Recent studies reported the presence of somatic
oncogenic mutations in the B-RAF gene, a member of
the RAF family, in a large percentage of human mela-
nomas and less frequently in a wide range of other hu-
man cancers such as colorectal, thyroid and lung cancer
[3, 13, 14, 18]. The great majority of mutations are lo-
cated in exon 15, with additional mutations also present
in exon 11. These mutations lead to constitutive acti-
vation of the RAF/MEK/ERK pathway and are onco-
genic in human cell lines [3, 21]. Interestingly, the B-RAF
and RAS mutations occur frequently in mutually
exclusive fashion in various tumors, suggesting a linear
functional relationship for these components in the
complex signaling pathways [3, 14, 18]. Davies et al. [3]
reported a low frequency (11%) of B-RAF mutation in
glioma cell lines, and the absence of B-RAF mutation in
a limited series primary glioma tumors.
In the current study we aimed to evaluate the afore-
mentioned observations in a larger series of primary
astrocytic and oligodendroglial tumors. We therefore
analyzed 82 cases for the presence of mutations in exon
11 and exon 15, to determine the role of B-RAF muta-
tion in the development and progression of these tu-
mors.
Material and methods
Tissue samples
Eighty-two formalin-ﬁxed and paraﬃn-embedded gli-
oma tumors were collected at the Department of
Pathology of Hospital Sa˜o Joa˜o, Porto and Hospital
Sa˜o Marcos, Braga, Portugal. All cases were reviewed by
two pathologists (J.M.L. and F.P.) and classiﬁed
according to the WHO classiﬁcation of CNS tumors
[10]. Forty-nine cases were astrocytic tumors, including
15 diﬀuse ﬁbrillary astrocytomas (WHO grade II), and
34 glioblastomas (WHO grade IV). Except for one case,
all glioblastomas were clinically de novo. Of the 33 oli-
godendroglial tumors, 15 were oligodendroglioma
(WHO grade II) and 18 were anaplastic oligodendro-
glioma (WHO grade III). Median age and gender of the
patients per tumor type is shown in Table 1. None of the
patients had a history of familiar cancer clustering.
DNA preparation
Tumor DNA was obtained from paraﬃn sections as
previously described, with some modiﬁcations [16].
Brieﬂy, serial 10-lm-thick unstained sections of paraﬃn
blocks were cut, and one hematoxylin and eosin-stained
section was taken for identiﬁcation and selection of the
tumor portion. Selected areas contained at least 85% of
tumor tissue. Constitutive DNA analysis was not per-
formed due to restriction of non-tumor tissue of the
patients. Paraﬃn was removed by incubation in xylene,
followed by ethanol washing, drying and digestion in
100 ll lysis buﬀer (500 mM TRIS-HCl pH 8.5, 1 mM
EDTA pH 8.0) containing proteinase K to a ﬁnal con-
centration of 0.5 mg/ml) at 55C for 48 h. After pro-
teinase K denaturation, DNA samples were stored at
20C for subsequent molecular analysis.
B-RAF mutation analysis
Screening for exon 11 and 15 mutations was performed
by polymerase chain reaction-single strand conforma-
tional polymorphism (PCR-SSCP) techniques using
genomic DNA. PCR was processed as described else-
where [18]. Brieﬂy, ampliﬁcation was carried out in a total
volume of 25 ll, comprising 2 ll DNA solution, 1 U Taq
DNA polymerase (Platinum-Invitrogen, CA), 1.5 mM
MgCl2 (Invitrogen), 0.2 mM of each dNTP (Fermentas,
CA), 0.6 lMof both sense and antisense primers, 20 mM
TRIS-HCl pH 8.4 (Invitrogen) and 50 mM KCl buﬀer
(Invitrogen). PCR ampliﬁcation was performed in a
Biotech Primus 96 Plus Thermal Cycler, with an initial
denaturation step at 95C for 5 min, then ampliﬁed for
Table 1 Clinical pathological
features and frequency of B-
RAF mutations in gliomas
(n=82)
Tumor type (WHO grade) n Age (years) Male/Female B-RAF
(Mean ± SD) Exon 11 Exon 15
Astrocytic
Diﬀuse astrocytoma (II) 15 33.06 ± 13.63 8/7 0/15 (0%) 0/13 (0%)
Glioblastoma (IV) 34 59.2 ± 12.3 16/18 0/31 (0%) 2/34 (6%)
Oligodendroglial
Oligodendroglioma (II) 15 41.33 ± 14.36 9/6 0/15 (0%) 0/14 (0%)
Anaplastic oligodendroglioma (III) 18 55.72 ± 11.32 10/8 0/18 (0%) 0/16 (0%)
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38 cycles of denaturation at 95C for 45 s, annealing
(58C for exon 11, 60C for exon 15) for 45 s, extension
at 72C for 45 s, and ﬁnal extension step at 72C for
10 min. Primers sequence for exon 11 were: 5’-ATA-
AGGTTTTCTTTTTCTGTTTGGC-3’ (forward) and
5’-ACTTGTCACAATGTCACCACATTAC-3’ (reverse)
and as previously reported for exon 15, 5’-TCA-
TAATGCTTGCTCTGATAGGA-3’ (forward) and
5’-GGCCAAAAATTTAATCAGTGGA-3’ (reverse) [3].
The PCR product was then analyzed by SSCP: 18 ll
PCR product was mixed with 18 ll loading dye (98%
formamide and 10 mM EDTA, pH 8.0), denatured at
94C for 10 min and quenched on ice. Of the mixture,
12 ll were loaded onto 0.8· MDE gel (Cambrex,
Rockland, ME) at 180 V, for 16 h, at 4C. The gels were
silver stained. PCR products showing mobility shifts
were then puriﬁed using MicroSpinTM S-300 HR col-
umns (Pharmacia Biotech, Uppsala), submitted to a
cycle sequencing reaction using an ABI PRISM BigDye
Terminator Cycle Sequencing Ready Reaction Kit
(Perkin-Elmer) and analyzed with an ABI PRISM 3100
Genetic Analyzer. Samples presenting altered bands
were ampliﬁed and sequenced twice.
Results
The mutation screening of B-RAF exon 15 by PCR-
SSCP (Fig. 1), followed by direct sequencing showed the
presence of the hotspot V600E mutation (formerly re-
ferred as codon 599) [12] in 2 out of 34 glioblastomas,
corresponding to a mutation frequency of 6% (Fig. 2,
Table 1). In both cases there was no non-tumoral tissue
available for the screening of B-RAF mutations. The
tumor in one of the cases recurred, and the V600E
mutation was also present in the second glioblastoma
biopsy. Clinically, both mutated glioblastomas were
de novo and occurred in young adult patients (41 and
46 years old). All the other astrocytic tumors and the 33
oligodendroglial tumors were negative for exon 15. The
mutation analysis of B-RAF exon 11 showed the absence
of mutations in the astrocytic and oligodendroglial
tumors analyzed (Table 1).
Discussion
The RAF kinase family consist of three members: A-, B-
and C-RAF (also known as RAF-1), with regulatory
properties in RAS signal transduction cascade that
regulates cell proliferation and diﬀerentiation in re-
sponse to growth factors, cytokines and hormones [17].
Activated RAS induce phosphorylation and activation
of RAF serine/threonine kinases, triggering sequential
phosphorylation and activation of MEK and ERK [11].
Although the oncogenic potential of RAF (particularly
of C-RAF in in vitro models) has been known for a long
time [15], it is only recently that a large-scale screen for
genes mutated in cancer has reported the presence of
somatic B-RAF mutations in human tumors, including
melanomas, colorectal, lung and thyroid cancers [3, 13,
14, 18]. The most frequent mutation is a single trans-
version in exon 15 (T1799A), which accounts for 90% of
B-RAF mutations in human cancers, and leads to a
substitution of valine by glutamic acid at position 600
(V600E) in the B-RAF kinase activation domain [3]. A
second hotspot region for B-RAF mutation was found in
exon 11, and frequently involves a substitution of a
glycine to an alanine at residue 469 (G469A) due to
change of a guanine to a cytosine at position 1406
(G1406C) [3]. The primary consequence of both (V600E
and G469A) mutant proteins is a higher kinase activity,
which through distinct mechanisms stimulates ERK
activity independently of RAS status [21], inducing in
vitro transformation of human NIH3T3 cell lines [3].
The results of the present study show that B-RAF
mutations are not a frequent event in gliomas, in con-
currence with a previous report [3]. We observed the
presence of B-RAF mutations in 6% of glioblastomas
and the absence of such mutations in the other histo-
Fig. 1 PCR-SSCP analysis of exon 15 of the B-RAF gene. Lane 1:
control DNA; lane 2: DNA from a glioblastoma with normal band
pattern; lane 3: DNA from an anaplastic oligodendroglioma with
normal band pattern; lane 4: DNA from a glioblastoma with
V600E band shift (white arrow)
Fig. 2 Sequencing analysis of B-RAF indicating a thymine to
adenine substitution at codon 600, resulting in a substitution of a
valine to a glutamic acid (black arrow)
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logical types. At variance with melanoma, where B-RAF
mutations are an early event [13], in gliomas the presence
of mutations exclusively in high-grade lesions suggests
that they may represent a late event in the gliomagenesis.
In line with previous studies, the mutations identiﬁed
were in the hotspot V600E, indicating that RAF/MEK/
ERK cascade is constitutively activated in these tumors.
Although we have only analyzed two exons of the B-
RAF gene, hitherto no other activating mutations have
been identiﬁed outside of these hotspot exons [3, 21].
Due to the low number of B-RAF mutated cases, we
could not assess the putative association of B-RAF
activation with clinical and pathological feature of gli-
omas.
The RAS/RAF/MEK/ERK pathway mediates sev-
eral hallmarks of cancer. The low frequency of B-RAF
mutations observed in this and a previous study [3], and
the reported absence of RAS and C-RAF mutations in
gliomas [2, 3], is consistent with other alterations pos-
sibly occurring upstream the RAS/RAF pathway in
gliomas. The ampliﬁcation and/or overexpression of
growth factor receptors such as EGFR and PDGFR are
frequently encountered in gliomas [22].
Based on the low frequency of B-RAF mutations
observed, we concluded that B-RAF activation is not a
major event in glioma pathogenesis. Nevertheless, due to
the lack of eﬀective treatment for glioblastoma, it is
possible that those tumors with B-RAFmutations can be
candidate for a therapy involving RAF-pathway inhib-
itors [1].
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